Abstract
Coronary artery disease is the major cause of mortalilty in the West with coronary artery bypass surgery (CABG) being a means of restoring blood supply to ischaemic myocardium. The long saphenous vein is the most commonly used bypass conduit but its patency is inferior to the internal thoracic artery, the ‘gold standard’ graft. In conventional procedures the saphenous vein is harvested in such a manner that considerable vascular damage is inflicted. The structures mainly affected by this vascular trauma are the endothelium, autonomic nerves and vascular smooth muscle all containing cells with the potential to release nitric oxide (NO). While the majority of studies into the potential role of NO in vein graft performance have focussed on the involvement of endothelial nitric oxide synthase (eNOS) less information is available regarding the role of the inducible isoform of nitric oxide synthase (iNOS). While the effects of eNOS-derived NO are principally beneficial, iNOS is generally associated with pathological conditions. While potential pathophysiological roles of iNOS are discussed in this review we also outline many studies suggesting that this isoenzyme plays an important role in maintaing vein graft patency in patients undergoing CABG, particularly when the saphenous vein is harvested with minimal surgical trauma.
Keywords: Human saphenous vein, bypass graft, iNOS, nitric oxide, coronary artery disease.
Current Vascular Pharmacology
Title:Inducible Nitric Oxide Synthase and Vein Graft Performance in Patients Undergoing Coronary Artery Bypass Surgery: Physiological or Pathophysiological Role?
Volume: 12 Issue: 1
Author(s): Michael R. Dashwood and Andrzej Loesch
Affiliation:
Keywords: Human saphenous vein, bypass graft, iNOS, nitric oxide, coronary artery disease.
Abstract: Coronary artery disease is the major cause of mortalilty in the West with coronary artery bypass surgery (CABG) being a means of restoring blood supply to ischaemic myocardium. The long saphenous vein is the most commonly used bypass conduit but its patency is inferior to the internal thoracic artery, the ‘gold standard’ graft. In conventional procedures the saphenous vein is harvested in such a manner that considerable vascular damage is inflicted. The structures mainly affected by this vascular trauma are the endothelium, autonomic nerves and vascular smooth muscle all containing cells with the potential to release nitric oxide (NO). While the majority of studies into the potential role of NO in vein graft performance have focussed on the involvement of endothelial nitric oxide synthase (eNOS) less information is available regarding the role of the inducible isoform of nitric oxide synthase (iNOS). While the effects of eNOS-derived NO are principally beneficial, iNOS is generally associated with pathological conditions. While potential pathophysiological roles of iNOS are discussed in this review we also outline many studies suggesting that this isoenzyme plays an important role in maintaing vein graft patency in patients undergoing CABG, particularly when the saphenous vein is harvested with minimal surgical trauma.
Export Options
About this article
Cite this article as:
Dashwood R. Michael and Loesch Andrzej, Inducible Nitric Oxide Synthase and Vein Graft Performance in Patients Undergoing Coronary Artery Bypass Surgery: Physiological or Pathophysiological Role?, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/157016111201140327164409
DOI https://dx.doi.org/10.2174/157016111201140327164409 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal Allograft Thrombosis
Current Pediatric Reviews Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Gender Disparities in the Prevalence, Awareness, Treatment, and Control of High Blood Pressure
Current Pharmaceutical Design Transcription Factor Co-expression Networks of Adipose RNA-Seq Data Reveal Regulatory Mechanisms of Obesity
Current Genomics An Assessment of Patients Factors Effect on Prescriber Adherence to Ischemic Stroke Secondary Prevention Guidelines
Current Reviews in Clinical and Experimental Pharmacology Glucose and LDL Lowering: The Need for Intensive Therapy
Current Vascular Pharmacology In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Evaluation of In Vivo Efficacy of Aqueous Extract of Aerial Parts of Cynodon dactylon in Rats with Simultaneous Type 2 Diabetes and Hypertension
Current Bioactive Compounds Blockage of Central Sphingosine-1-phosphate Receptor does not Abolish the Protective Effect of FTY720 in Early Brain Injury after Experimental Subarachnoid Hemorrhage
Current Drug Delivery Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial (Thematic Issue: NADPH Oxidase-Derived ROS Signaling and Therapeutic Opportunities)
Current Pharmaceutical Design Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Association Between Sarcopenic Obesity and Metabolic Syndrome in Adults: A Systematic Review and Meta-Analysis
Current Cardiology Reviews Subject Index To Volume 2
Current Rheumatology Reviews Ambulatory Blood Pressure Monitoring in Prehypertensive Subjects
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology